Thermo Fisher issues €1.25B in 3.200%/3.650% notes due 2026/2034 and $1.2B in 4.800%/4.950% notes due 2027/2032

USD Offering On November 21, 2022, the Company issued $600,000,000 aggregate principal amount of 4.800% Senior Notes due 2027 (the “2027 Notes”) and $600,000,000 aggregate principal amount of 4.950% Senior Notes due 2032 (the “2032 Notes” and, together with the 2027 Notes, the “USD Notes”) in a public offering (the “USD Offering”) pursuant to a registration statement on Form S-3 (File No. 333-263034) and a preliminary prospectus supplement and prospectus supplement related to the offering of the USD Notes, each as previously filed with the SEC. The USD Notes were issued under the Base Indenture and the Twenty-Sixth Supplemental Indenture, dated as of November 21, 2022 (the “USD Supplemental Indenture” and, together with the Base Indenture, the “USD Indenture”), between the Company and the Trustee.

On November 21, 2022, Thermo Fisher Scientific Inc. (the “Company”) issued €500,000,000 aggregate principal amount of 3.200% Senior Notes due 2026 (the “2026 Notes”) and €750,000,000 aggregate principal amount of 3.650% Senior Notes due 2034 (the “2034 Notes”, and, together with the 2026 Notes, the “Euro Notes”) in a public offering (the “Euro Offering”) pursuant to a registration statement on Form S-3 (File No. 333-263034) and a preliminary prospectus supplement and prospectus supplement related to the offering of the Euro Notes, each as previously filed with the Securities and Exchange Commission (the “SEC”). The Euro Notes were issued under an indenture, dated as of November 20, 2009 (the “Base Indenture”), and the Twenty-Fifth Supplemental Indenture, dated as of November 21, 2022 (the “Euro Supplemental Indenture” and, together with the Base Indenture, the “Euro Indenture”), between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Truste